Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generic Drugs Office’s Scientific Advisory Team Will Direct Research

Executive Summary

Studies of bioequivalence methods by FDA's Office of Generic Drugs will be directed by its Research Initiatives Committee

You may also be interested in...



FDA Generic Drug Promotional Campaign Features Newspaper Articles

FDA's educational campaign to encourage the use of generic drugs will be launched in late July with an informational article appearing in local newspapers nationwide

DPK guidance to be withdrawn

FDA will withdraw draft guidance on dermatopharmacokinetics. "We are going to focus on a variety of other methods that make it possible for bioequivalence" for topical dermatologic products, Office of Pharmaceutical Science Acting Director Helen Winkle told the Generic Pharmaceutical Association's annual meeting in Coral Gables, Fla., April 10. "This is not to say that DPK is completely off the radar screen - we will continue to look at it - but we felt like we wanted to get the guidance out of publication." The agency has been considering alternatives following an unfavorable advisory committee meeting (1"The Pink Sheet" Dec. 17, 2001, p. 40)...

Generic Drug Patent Challenge Notifications Will Be Announced By FDA

FDA will soon begin posting announcements of ANDAs that have been filed with Paragraph IV certification on the Office of Generic Drugs web site.

UsernamePublicRestriction

Register

PS040648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel